Drug reg­u­la­tors look to har­mo­nize how they tack­le in­no­va­tion

The In­ter­na­tion­al Coali­tion of Med­i­cines Reg­u­la­to­ry Au­thor­i­ties (ICM­RA) re­cent­ly re­leased a re­port on how var­i­ous reg­u­la­tors world­wide are work­ing to­geth­er to bet­ter iden­ti­fy and ad­dress fu­ture reg­u­la­to­ry chal­lenges posed by new cat­e­gories of ther­a­peu­tics, like cell and gene ther­a­pies, and new tools for drug de­vel­op­ment, such as ar­ti­fi­cial in­tel­li­gence (AI).

The re­port, which is part of a wider ef­fort to re­duce du­plica­tive work and in­crease har­mo­niza­tion among drug reg­u­la­tors from the US, Eu­rope, Japan and else­where, delves in­to the top­ic of hori­zon scan­ning for new in­no­va­tions, which for most reg­u­la­tors is “still in its in­fan­cy.” The re­port al­so ad­dress­es nov­el reg­u­la­to­ry path­ways, such as ex­pe­dit­ed path­ways, and oth­ers re­lat­ed to ear­ly en­gage­ment with stake­hold­ers, such as Health Tech­nol­o­gy As­sess­ment agen­cies.

“The pace of in­no­va­tion in med­ical de­vices has sur­passed med­i­cines due adapt­able ap­proach­es to the reg­u­la­tion of in­no­v­a­tive prod­ucts. While the ex­ist­ing nov­el li­cenc­ing path­ways for med­i­cines have seen pos­i­tive re­sults in pro­vid­ing time­ly pa­tient ac­cess, cur­rent and up­com­ing in­no­va­tions will con­tin­ue to chal­lenge reg­u­la­tors,” the re­port notes.

Eu­ro­pean, Japan­ese and Sin­ga­pore drug reg­u­la­tors al­so fur­ther ex­plored the top­ics of ad­di­tive man­u­fac­tur­ing, genome edit­ing and AI.

“The prod­ucts and tech­nolo­gies ex­plored in the case stud­ies show that many reg­u­la­to­ry sci­ence tools are miss­ing at present (e.g. off-tar­get ef­fects de­tec­tion meth­ods) and must be de­vel­oped in or­der for reg­u­la­tors to be able to as­sess the prod­ucts across their life-cy­cle. In ad­di­tion, new tech­nolo­gies (such as ad­di­tive man­u­fac­tur­ing) re­quire adap­ta­tion of the ex­ist­ing reg­u­la­to­ry frame­works, as they fa­cil­i­tate the pro­duc­tion of more com­plex prod­ucts at the point of care rather than in ded­i­cat­ed man­u­fac­tur­ing sites,” the re­port adds.

Reg­u­la­tors will need to train staffers on the new prod­uct types, but will al­so have to ac­cess out­side ex­perts (e.g., soft­ware en­gi­neers), who will re­quire reg­u­la­to­ry train­ing, as well. The agen­cies pro­posed de­vel­op­ing a ca­pac­i­ty frame­work for ex­per­tise as a com­mon re­source, fea­tur­ing the map­ping of the re­quired skills and ex­per­tise for var­i­ous types of prod­ucts or tech­nolo­gies to as­sist reg­u­la­tors in iden­ti­fy­ing their ca­pac­i­ty needs.

ICM­RA, which is al­so look­ing to es­tab­lish an in­for­mal in­no­va­tion net­work among ICM­RA mem­bers lat­er this year, will seek to bet­ter ar­tic­u­late the com­mon char­ac­ter­is­tics of nov­el reg­u­la­to­ry path­ways and to as­sist the analy­ses and con­sid­er­a­tions of new and ex­ist­ing reg­u­la­to­ry meth­ods.

In ad­di­tion to the strate­gic pri­or­i­ty project re­port on in­no­va­tion, ICM­RA re­cent­ly re­leased a frame­work for the in­volve­ment of health au­thor­i­ties in the man­age­ment of glob­al health crises.

In­no­va­tion Strate­gic Pri­or­i­ty Pro­ject Re­port

First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Im­age: Shut­ter­stock


Zachary Brennan

managing editor, RAPS

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.

Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jeffrey Kindler’s plan to take his biotech — which is developing a slate of non-opioid painkillers — public, is back on.

The Boston based company, led by former Pfizer $PFE chief Kindler, originally contemplated a $70 million to $80 million IPO last year— but eventually postponed that strategy. On Wednesday, the company revived its bid to make a public debut in a filing with the SEC — although no pricing details were disclosed.

Zachary Hornby. Boundless

'A fourth rev­o­lu­tion in can­cer ther­a­pies': ARCH-backed Bound­less Bio flash­es big check, makes big­ger promis­es in de­but

It was the cellular equivalent of opening your car door and finding an active, roaring engine in the driver seat.

Scientists learned strands of DNA could occasionally appear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diego’s Paul Mischel published his first study in Science in 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors’ superhuman growth.

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck helps bankroll new part­ner Themis' game plan to fin­ish the chikun­gun­ya race and be­gin on­colyt­ic virus quest

As Themis gears up for a Phase III trial of its chikungunya vaccine, the Vienna-based biotech has closed out €40 million ($44 million) to foot the clinical and manufacturing bills.

Its heavyweight partners at Merck — which signed a pact around a mysterious “blockbuster indication” last month — jumped into the Series D, led by new investors Farallon Capital and Hadean Ventures. Adjuvant Capital also joined, as did current investors Global Health Investment Fund, aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences.